On Monday, Tim Anderson, a sell-side analyst at Prudential Equities, wrote in a research note that he and his team believe that Bristol carefully designed Prove-It to show the drugs are the same, perhaps by making the study too small or too short.

FORBES: Bristol Prepares Shot In Statin War

Much is now being said about the fact that individual investors are finally becoming bullish and optimistic, perhaps too much so given that usually savvy corporate insiders are now selling heavily and the market is short-term overbought.

FORBES: Two Years Of Fears Disappear